ClinicalTrials.gg

Program

Pneumococcal Conjugate Vaccine

Also written as “Multivalent”, “Pneumococcal Conjugate Vaccine (V114)” and “Pneumococcal conjugate vaccine”.

Its studies are mostly in Pneumococcal Infections, led by 4 companies.

Furthest: phase 2, since Apr 11, 20185 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer20 open or runningphase 2since Apr 11, 2018Apr 11, 2018none ahead
LG Chem10 open or runningphase 1since Sep 2, 2016Sep 2, 2016none ahead
Merck10 open or runningphase 2since Dec 27, 2011Dec 27, 2011none ahead
Sanofi10 open or runningphase 1since Nov 18, 2024Nov 18, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 27, 2011First study: phase 2 study in Pneumococcal InfectionsNew to MerckMerck · NCT01513551 · 692 enrolled
  2. Sep 2, 2016LG Chem’s first study: phase 1 study in Pneumococcal InfectionsNew to LG ChemLG Chem · NCT02892812 · 63 enrolled · Korea, Republic of
  3. Apr 11, 2018Pfizer’s first study: phase 2 study in Pneumococcal InfectionsNew to PfizerPfizer · NCT03512288 · 460 enrolled · United States
  4. May 25, 2018Phase 2 study in Pneumococcal InfectionsPfizer · NCT03550313 · 565 enrolled · United States
  5. Nov 18, 2024Sanofi’s first study: phase 1 study in Pneumococcal ImmunizationNew to SanofiSanofi · NCT06698198 · 175 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“An active immunizing vaccine used to prevent infection by the bacterium Streptococcus pneumoniae”NCIt, by rule
“Pneumococcal Conjugate Vaccine”name, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06698198Pneumococcal Immunization · United States1CompletedSanofiSep 30, 2019175
NCT03550313Pneumococcal Infections · United States2TerminatedPfizerNov 5, 2020565
NCT03512288Pneumococcal Infections · United States2CompletedPfizerFeb 11, 2020460
NCT02892812Pneumococcal Infections · Korea, Republic of1CompletedLG ChemNov 201663
NCT01513551Pneumococcal Infections2CompletedMerckFeb 15, 2013692

How it is read

Names in the registry

  • “Multivalent”, 2 entries
  • “Pneumococcal Conjugate Vaccine”, 1 entry
  • “Pneumococcal Conjugate Vaccine (V114)”, 1 entry
  • “Pneumococcal conjugate vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.